CovidStanfordV1, Main, Exploration, bibRecord, 000289

Safety of Plasma Infusions in Parkinson's Disease.

Identifieur interne : 000289 ( Main/Exploration ); précédent : 000288; suivant : 000290

Safety of Plasma Infusions in Parkinson's Disease.

Auteurs : Jordan E. Parker [États-Unis] ; Amaris Martinez [États-Unis] ; Gayle K. Deutsch [États-Unis] ; Varsha Prabhakar [États-Unis] ; Melanie Lising [États-Unis] ; Kristopher I. Kapphahn [États-Unis] ; Chioma M. Anidi [États-Unis] ; Raumin Neuville [États-Unis] ; Maria Coburn [États-Unis] ; Neil Shah [États-Unis] ; Helen M. Bronte-Stewart [États-Unis]

Source :

Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2020.

RBID : pubmed:32633860

Descripteurs français

KwdFr :
- Adulte d'âge moyen (MeSH), Antiparkinsoniens (usage thérapeutique), Association thérapeutique (MeSH), Facteur de nécrose tumorale alpha (sang), Femelle (MeSH), Humains (MeSH), Indice de gravité de la maladie (MeSH), Interleukine-6 (sang), Maladie de Parkinson (psychologie), Maladie de Parkinson (sang), Maladie de Parkinson (thérapie), Mâle (MeSH), Phénomènes biomécaniques (MeSH), Plasma sanguin (MeSH), Risque (MeSH), Stimulation cérébrale profonde (MeSH), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Tests neuropsychologiques (MeSH), Transfusion de composants du sang (effets indésirables), Troubles de la cognition (thérapie), Troubles de la cognition (étiologie), Troubles de la parole (thérapie), Troubles de la parole (étiologie), Vieillissement (sang), Études de faisabilité (MeSH).
MESH :
- effets indésirables : Transfusion de composants du sang.
- psychologie : Maladie de Parkinson.
- sang : Facteur de nécrose tumorale alpha, Interleukine-6, Maladie de Parkinson, Vieillissement.
- thérapie : Maladie de Parkinson, Troubles de la cognition, Troubles de la parole.
- usage thérapeutique : Antiparkinsoniens.
- étiologie : Troubles de la cognition, Troubles de la parole.
- Adulte d'âge moyen, Association thérapeutique, Femelle, Humains, Indice de gravité de la maladie, Mâle, Phénomènes biomécaniques, Plasma sanguin, Risque, Stimulation cérébrale profonde, Sujet âgé, Sujet âgé de 80 ans ou plus, Tests neuropsychologiques, Études de faisabilité.

English descriptors

KwdEn :
- Aged (MeSH), Aged, 80 and over (MeSH), Aging (blood), Antiparkinson Agents (therapeutic use), Biomechanical Phenomena (MeSH), Blood Component Transfusion (adverse effects), COVID-19 (epidemiology), Cognition Disorders (etiology), Cognition Disorders (therapy), Combined Modality Therapy (MeSH), Deep Brain Stimulation (MeSH), Feasibility Studies (MeSH), Female (MeSH), Humans (MeSH), Interleukin-6 (blood), Male (MeSH), Middle Aged (MeSH), Neuropsychological Tests (MeSH), Parkinson Disease (blood), Parkinson Disease (psychology), Parkinson Disease (therapy), Plasma (MeSH), Risk (MeSH), Severity of Illness Index (MeSH), Speech Disorders (etiology), Speech Disorders (therapy), Tumor Necrosis Factor-alpha (blood).
MESH :
- chemical , blood : Interleukin-6, Tumor Necrosis Factor-alpha.
- chemical , therapeutic use : Antiparkinson Agents.
- adverse effects : Blood Component Transfusion.
- blood : Aging, Parkinson Disease.
- epidemiology : COVID-19.
- etiology : Cognition Disorders, Speech Disorders.
- psychology : Parkinson Disease.
- therapy : Cognition Disorders, Parkinson Disease, Speech Disorders.
- Aged, Aged, 80 and over, Biomechanical Phenomena, Combined Modality Therapy, Deep Brain Stimulation, Feasibility Studies, Female, Humans, Male, Middle Aged, Neuropsychological Tests, Plasma, Risk, Severity of Illness Index.

Abstract

BACKGROUND

Young plasma infusions have emerged as a potential treatment for neurodegenerative disease, and convalescent plasma therapy has been used safely in the management of viral pandemics. However, the effect of plasma therapy in Parkinson's disease (PD) is unknown.

OBJECTIVES

The objective of this study was to determine the safety, tolerability, and feasibility of plasma infusions in people with PD.

METHODS

A total of 15 people with clinically established PD, at least 1 cognitive complaint, and on stable therapy received 1 unit of young fresh frozen plasma twice a week for 4 weeks. Assessments and adverse effects were performed/reported on and off therapy at baseline, immediately after, and 4 weeks after the infusions ended. Adverse effects were also assessed during infusions. The primary outcomes were safety, tolerability, and feasibility. Exploratory outcomes included Unified Parkinson's Disease Rating Scale Part III off medication, neuropsychological battery, Parkinson's Disease Questionnaire-39, inflammatory markers (tumor necrosis factor-α, interleukin-6), uric acid, and quantitative kinematics.

RESULTS

Adherence rate was 100% with no serious adverse effects. There was evidence of improvement in phonemic fluency (P = 0.002) and in the Parkinson's Disease Questionnaire-39 stigma subscore (P = 0.013) that were maintained at the delayed evaluation. Elevated baseline tumor necrosis factor-α levels decreased 4 weeks after the infusions ended.

CONCLUSIONS

Young fresh frozen plasma was safe, feasible, and well tolerated in people with PD, without serious adverse effects and with preliminary evidence for improvements in phonemic fluency and stigma. The results of this study warrant further therapeutic investigations in PD and provide safety and feasibility data for plasma therapy in people with PD who may be at higher risk for severe complications of COVID-19. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

DOI: 10.1002/mds.28198
PubMed: 32633860
PubMed Central: PMC7361360

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000533
to stream Main, to step Curation: 000533

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety of Plasma Infusions in Parkinson's Disease.</title>
<author><name sortKey="Parker, Jordan E" sort="Parker, Jordan E" uniqKey="Parker J" first="Jordan E" last="Parker">Jordan E. Parker</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martinez, Amaris" sort="Martinez, Amaris" uniqKey="Martinez A" first="Amaris" last="Martinez">Amaris Martinez</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deutsch, Gayle K" sort="Deutsch, Gayle K" uniqKey="Deutsch G" first="Gayle K" last="Deutsch">Gayle K. Deutsch</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Prabhakar, Varsha" sort="Prabhakar, Varsha" uniqKey="Prabhakar V" first="Varsha" last="Prabhakar">Varsha Prabhakar</name>
<affiliation wicri:level="2"><nlm:affiliation>Miller School of Medicine, University of Miami, Miami, Florida, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Miller School of Medicine, University of Miami, Miami, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lising, Melanie" sort="Lising, Melanie" uniqKey="Lising M" first="Melanie" last="Lising">Melanie Lising</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kapphahn, Kristopher I" sort="Kapphahn, Kristopher I" uniqKey="Kapphahn K" first="Kristopher I" last="Kapphahn">Kristopher I. Kapphahn</name>
<affiliation wicri:level="2"><nlm:affiliation>Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Anidi, Chioma M" sort="Anidi, Chioma M" uniqKey="Anidi C" first="Chioma M" last="Anidi">Chioma M. Anidi</name>
<affiliation wicri:level="2"><nlm:affiliation>School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>School of Medicine, University of Michigan, Ann Arbor, Michigan</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Neuville, Raumin" sort="Neuville, Raumin" uniqKey="Neuville R" first="Raumin" last="Neuville">Raumin Neuville</name>
<affiliation wicri:level="2"><nlm:affiliation>School of Medicine, University of California, Irvine, Irvine, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>School of Medicine, University of California, Irvine, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coburn, Maria" sort="Coburn, Maria" uniqKey="Coburn M" first="Maria" last="Coburn">Maria Coburn</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurosurgery, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shah, Neil" sort="Shah, Neil" uniqKey="Shah N" first="Neil" last="Shah">Neil Shah</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bronte Stewart, Helen M" sort="Bronte Stewart, Helen M" uniqKey="Bronte Stewart H" first="Helen M" last="Bronte-Stewart">Helen M. Bronte-Stewart</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurosurgery, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:32633860</idno>
<idno type="pmid">32633860</idno>
<idno type="doi">10.1002/mds.28198</idno>
<idno type="pmc">PMC7361360</idno>
<idno type="wicri:Area/Main/Corpus">000533</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000533</idno>
<idno type="wicri:Area/Main/Curation">000533</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000533</idno>
<idno type="wicri:Area/Main/Exploration">000533</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Safety of Plasma Infusions in Parkinson's Disease.</title>
<author><name sortKey="Parker, Jordan E" sort="Parker, Jordan E" uniqKey="Parker J" first="Jordan E" last="Parker">Jordan E. Parker</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Martinez, Amaris" sort="Martinez, Amaris" uniqKey="Martinez A" first="Amaris" last="Martinez">Amaris Martinez</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Deutsch, Gayle K" sort="Deutsch, Gayle K" uniqKey="Deutsch G" first="Gayle K" last="Deutsch">Gayle K. Deutsch</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Prabhakar, Varsha" sort="Prabhakar, Varsha" uniqKey="Prabhakar V" first="Varsha" last="Prabhakar">Varsha Prabhakar</name>
<affiliation wicri:level="2"><nlm:affiliation>Miller School of Medicine, University of Miami, Miami, Florida, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Miller School of Medicine, University of Miami, Miami, Florida</wicri:regionArea>
<placeName><region type="state">Floride</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lising, Melanie" sort="Lising, Melanie" uniqKey="Lising M" first="Melanie" last="Lising">Melanie Lising</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Kapphahn, Kristopher I" sort="Kapphahn, Kristopher I" uniqKey="Kapphahn K" first="Kristopher I" last="Kapphahn">Kristopher I. Kapphahn</name>
<affiliation wicri:level="2"><nlm:affiliation>Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Anidi, Chioma M" sort="Anidi, Chioma M" uniqKey="Anidi C" first="Chioma M" last="Anidi">Chioma M. Anidi</name>
<affiliation wicri:level="2"><nlm:affiliation>School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>School of Medicine, University of Michigan, Ann Arbor, Michigan</wicri:regionArea>
<placeName><region type="state">Michigan</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Neuville, Raumin" sort="Neuville, Raumin" uniqKey="Neuville R" first="Raumin" last="Neuville">Raumin Neuville</name>
<affiliation wicri:level="2"><nlm:affiliation>School of Medicine, University of California, Irvine, Irvine, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>School of Medicine, University of California, Irvine, Irvine, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Coburn, Maria" sort="Coburn, Maria" uniqKey="Coburn M" first="Maria" last="Coburn">Maria Coburn</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurosurgery, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Shah, Neil" sort="Shah, Neil" uniqKey="Shah N" first="Neil" last="Shah">Neil Shah</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Pathology, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bronte Stewart, Helen M" sort="Bronte Stewart, Helen M" uniqKey="Bronte Stewart H" first="Helen M" last="Bronte-Stewart">Helen M. Bronte-Stewart</name>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
<affiliation wicri:level="2"><nlm:affiliation>Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurosurgery, Stanford University School of Medicine, Stanford, California</wicri:regionArea>
<placeName><region type="state">Californie</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="eISSN">1531-8257</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged (MeSH)</term>
<term>Aged, 80 and over (MeSH)</term>
<term>Aging (blood)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Biomechanical Phenomena (MeSH)</term>
<term>Blood Component Transfusion (adverse effects)</term>
<term>COVID-19 (epidemiology)</term>
<term>Cognition Disorders (etiology)</term>
<term>Cognition Disorders (therapy)</term>
<term>Combined Modality Therapy (MeSH)</term>
<term>Deep Brain Stimulation (MeSH)</term>
<term>Feasibility Studies (MeSH)</term>
<term>Female (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Interleukin-6 (blood)</term>
<term>Male (MeSH)</term>
<term>Middle Aged (MeSH)</term>
<term>Neuropsychological Tests (MeSH)</term>
<term>Parkinson Disease (blood)</term>
<term>Parkinson Disease (psychology)</term>
<term>Parkinson Disease (therapy)</term>
<term>Plasma (MeSH)</term>
<term>Risk (MeSH)</term>
<term>Severity of Illness Index (MeSH)</term>
<term>Speech Disorders (etiology)</term>
<term>Speech Disorders (therapy)</term>
<term>Tumor Necrosis Factor-alpha (blood)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Adulte d'âge moyen (MeSH)</term>
<term>Antiparkinsoniens (usage thérapeutique)</term>
<term>Association thérapeutique (MeSH)</term>
<term>Facteur de nécrose tumorale alpha (sang)</term>
<term>Femelle (MeSH)</term>
<term>Humains (MeSH)</term>
<term>Indice de gravité de la maladie (MeSH)</term>
<term>Interleukine-6 (sang)</term>
<term>Maladie de Parkinson (psychologie)</term>
<term>Maladie de Parkinson (sang)</term>
<term>Maladie de Parkinson (thérapie)</term>
<term>Mâle (MeSH)</term>
<term>Phénomènes biomécaniques (MeSH)</term>
<term>Plasma sanguin (MeSH)</term>
<term>Risque (MeSH)</term>
<term>Stimulation cérébrale profonde (MeSH)</term>
<term>Sujet âgé (MeSH)</term>
<term>Sujet âgé de 80 ans ou plus (MeSH)</term>
<term>Tests neuropsychologiques (MeSH)</term>
<term>Transfusion de composants du sang (effets indésirables)</term>
<term>Troubles de la cognition (thérapie)</term>
<term>Troubles de la cognition (étiologie)</term>
<term>Troubles de la parole (thérapie)</term>
<term>Troubles de la parole (étiologie)</term>
<term>Vieillissement (sang)</term>
<term>Études de faisabilité (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Interleukin-6</term>
<term>Tumor Necrosis Factor-alpha</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Blood Component Transfusion</term>
</keywords>
<keywords scheme="MESH" qualifier="blood" xml:lang="en"><term>Aging</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Transfusion de composants du sang</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Cognition Disorders</term>
<term>Speech Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="psychologie" xml:lang="fr"><term>Maladie de Parkinson</term>
</keywords>
<keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Facteur de nécrose tumorale alpha</term>
<term>Interleukine-6</term>
<term>Maladie de Parkinson</term>
<term>Vieillissement</term>
</keywords>
<keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Cognition Disorders</term>
<term>Parkinson Disease</term>
<term>Speech Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="thérapie" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Troubles de la cognition</term>
<term>Troubles de la parole</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antiparkinsoniens</term>
</keywords>
<keywords scheme="MESH" qualifier="étiologie" xml:lang="fr"><term>Troubles de la cognition</term>
<term>Troubles de la parole</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Aged</term>
<term>Aged, 80 and over</term>
<term>Biomechanical Phenomena</term>
<term>Combined Modality Therapy</term>
<term>Deep Brain Stimulation</term>
<term>Feasibility Studies</term>
<term>Female</term>
<term>Humans</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Neuropsychological Tests</term>
<term>Plasma</term>
<term>Risk</term>
<term>Severity of Illness Index</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Adulte d'âge moyen</term>
<term>Association thérapeutique</term>
<term>Femelle</term>
<term>Humains</term>
<term>Indice de gravité de la maladie</term>
<term>Mâle</term>
<term>Phénomènes biomécaniques</term>
<term>Plasma sanguin</term>
<term>Risque</term>
<term>Stimulation cérébrale profonde</term>
<term>Sujet âgé</term>
<term>Sujet âgé de 80 ans ou plus</term>
<term>Tests neuropsychologiques</term>
<term>Études de faisabilité</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b>
</p>
<p>Young plasma infusions have emerged as a potential treatment for neurodegenerative disease, and convalescent plasma therapy has been used safely in the management of viral pandemics. However, the effect of plasma therapy in Parkinson's disease (PD) is unknown.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>OBJECTIVES</b>
</p>
<p>The objective of this study was to determine the safety, tolerability, and feasibility of plasma infusions in people with PD.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>METHODS</b>
</p>
<p>A total of 15 people with clinically established PD, at least 1 cognitive complaint, and on stable therapy received 1 unit of young fresh frozen plasma twice a week for 4 weeks. Assessments and adverse effects were performed/reported on and off therapy at baseline, immediately after, and 4 weeks after the infusions ended. Adverse effects were also assessed during infusions. The primary outcomes were safety, tolerability, and feasibility. Exploratory outcomes included Unified Parkinson's Disease Rating Scale Part III off medication, neuropsychological battery, Parkinson's Disease Questionnaire-39, inflammatory markers (tumor necrosis factor-α, interleukin-6), uric acid, and quantitative kinematics.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>RESULTS</b>
</p>
<p>Adherence rate was 100% with no serious adverse effects. There was evidence of improvement in phonemic fluency (P = 0.002) and in the Parkinson's Disease Questionnaire-39 stigma subscore (P = 0.013) that were maintained at the delayed evaluation. Elevated baseline tumor necrosis factor-α levels decreased 4 weeks after the infusions ended.</p>
</div>
<div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b>
</p>
<p>Young fresh frozen plasma was safe, feasible, and well tolerated in people with PD, without serious adverse effects and with preliminary evidence for improvements in phonemic fluency and stigma. The results of this study warrant further therapeutic investigations in PD and provide safety and feasibility data for plasma therapy in people with PD who may be at higher risk for severe complications of COVID-19. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</p>
</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32633860</PMID>
<DateCompleted><Year>2020</Year>
<Month>12</Month>
<Day>21</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>10</Day>
</DateRevised>
<Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>35</Volume>
<Issue>11</Issue>
<PubDate><Year>2020</Year>
<Month>11</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov Disord</ISOAbbreviation>
</Journal>
<ArticleTitle>Safety of Plasma Infusions in Parkinson's Disease.</ArticleTitle>
<Pagination><MedlinePgn>1905-1913</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.28198</ELocationID>
<Abstract><AbstractText Label="BACKGROUND">Young plasma infusions have emerged as a potential treatment for neurodegenerative disease, and convalescent plasma therapy has been used safely in the management of viral pandemics. However, the effect of plasma therapy in Parkinson's disease (PD) is unknown.</AbstractText>
<AbstractText Label="OBJECTIVES">The objective of this study was to determine the safety, tolerability, and feasibility of plasma infusions in people with PD.</AbstractText>
<AbstractText Label="METHODS">A total of 15 people with clinically established PD, at least 1 cognitive complaint, and on stable therapy received 1 unit of young fresh frozen plasma twice a week for 4 weeks. Assessments and adverse effects were performed/reported on and off therapy at baseline, immediately after, and 4 weeks after the infusions ended. Adverse effects were also assessed during infusions. The primary outcomes were safety, tolerability, and feasibility. Exploratory outcomes included Unified Parkinson's Disease Rating Scale Part III off medication, neuropsychological battery, Parkinson's Disease Questionnaire-39, inflammatory markers (tumor necrosis factor-α, interleukin-6), uric acid, and quantitative kinematics.</AbstractText>
<AbstractText Label="RESULTS">Adherence rate was 100% with no serious adverse effects. There was evidence of improvement in phonemic fluency (P = 0.002) and in the Parkinson's Disease Questionnaire-39 stigma subscore (P = 0.013) that were maintained at the delayed evaluation. Elevated baseline tumor necrosis factor-α levels decreased 4 weeks after the infusions ended.</AbstractText>
<AbstractText Label="CONCLUSIONS">Young fresh frozen plasma was safe, feasible, and well tolerated in people with PD, without serious adverse effects and with preliminary evidence for improvements in phonemic fluency and stigma. The results of this study warrant further therapeutic investigations in PD and provide safety and feasibility data for plasma therapy in people with PD who may be at higher risk for severe complications of COVID-19. © 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</AbstractText>
<CopyrightInformation>© 2020 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.</CopyrightInformation>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Parker</LastName>
<ForeName>Jordan E</ForeName>
<Initials>JE</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Martinez</LastName>
<ForeName>Amaris</ForeName>
<Initials>A</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Deutsch</LastName>
<ForeName>Gayle K</ForeName>
<Initials>GK</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Prabhakar</LastName>
<ForeName>Varsha</ForeName>
<Initials>V</Initials>
<AffiliationInfo><Affiliation>Miller School of Medicine, University of Miami, Miami, Florida, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lising</LastName>
<ForeName>Melanie</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kapphahn</LastName>
<ForeName>Kristopher I</ForeName>
<Initials>KI</Initials>
<AffiliationInfo><Affiliation>Quantitative Sciences Unit, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Anidi</LastName>
<ForeName>Chioma M</ForeName>
<Initials>CM</Initials>
<AffiliationInfo><Affiliation>School of Medicine, University of Michigan, Ann Arbor, Michigan, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Neuville</LastName>
<ForeName>Raumin</ForeName>
<Initials>R</Initials>
<AffiliationInfo><Affiliation>School of Medicine, University of California, Irvine, Irvine, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Coburn</LastName>
<ForeName>Maria</ForeName>
<Initials>M</Initials>
<AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Shah</LastName>
<ForeName>Neil</ForeName>
<Initials>N</Initials>
<AffiliationInfo><Affiliation>Department of Pathology, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Bronte-Stewart</LastName>
<ForeName>Helen M</ForeName>
<Initials>HM</Initials>
<Identifier Source="ORCID">0000-0002-1839-4541</Identifier>
<AffiliationInfo><Affiliation>Department of Neurology and Neurological Sciences, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Neurosurgery, Stanford University School of Medicine, Stanford, California, USA.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><Agency>Private philanthropic donation</Agency>
<Country>International</Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>07</Month>
<Day>07</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>United States</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001696" MajorTopicYN="N">Biomechanical Phenomena</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016913" MajorTopicYN="N">Blood Component Transfusion</DescriptorName>
<QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003072" MajorTopicYN="N">Cognition Disorders</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
<QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010949" MajorTopicYN="Y">Plasma</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012306" MajorTopicYN="N">Risk</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013064" MajorTopicYN="N">Speech Disorders</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName>
<QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">Parkinson's disease</Keyword>
<Keyword MajorTopicYN="Y">infusions</Keyword>
<Keyword MajorTopicYN="Y">plasma</Keyword>
<Keyword MajorTopicYN="Y">young plasma</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>04</Month>
<Day>24</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>05</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>06</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>7</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2020</Year>
<Month>12</Month>
<Day>22</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>7</Month>
<Day>8</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">32633860</ArticleId>
<ArticleId IdType="doi">10.1002/mds.28198</ArticleId>
<ArticleId IdType="pmc">PMC7361360</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>J Biomed Inform. 2009 Apr;42(2):377-81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18929686</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Invest. 2020 Jun 1;130(6):2757-2765</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32254064</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neural Transm (Vienna). 2014 Jan;121(1):33-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23913130</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurobiol Dis. 2016 Dec;96:22-30</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27553876</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Orthop Res. 2014 Apr;32(4):551-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24338609</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Neurol. 2019 Jan 1;76(1):35-40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30383097</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Neurol. 2015 Feb;11(2):80-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25561275</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>FASEB J. 2002 Sep;16(11):1474-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12205053</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Microbiol Rev. 2000 Oct;13(4):602-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">11023960</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biomed Res Int. 2014;2014:648740</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24900975</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Parkinsonism Relat Disord. 2005 Nov;11(7):435-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16154791</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antivir Ther. 2018;23(7):617-622</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29923831</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mov Disord. 2020 May;35(5):711-715</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32250460</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Int Neuropsychol Soc. 2004 Jul;10(4):608-22</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15327739</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15616839</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurology. 1967 May;17(5):427-42</Citation>
<ArticleIdList><ArticleId IdType="pubmed">6067254</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Qual Life Res. 2016 Dec;25(12):3037-3045</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27259581</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 Apr 28;323(16):1582-1589</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219428</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurobiol Aging. 2003 Mar-Apr;24(2):197-211</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12498954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Neurol. 2010 Jan;67(1):64-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">20065131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Intern Med. 2006 Oct 17;145(8):599-609</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16940336</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Exp Neuropsychol. 2014;36(3):278-89</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24533593</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Parkinsons Dis. 2020;10(2):351-354</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32250324</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mov Disord. 2008 Nov 15;23(15):2129-70</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19025984</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mov Disord. 2015 Oct;30(12):1591-601</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26474316</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Neurol. 2016 Nov 1;73(11):1325-1333</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27598869</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Clin Apher. 2020 Aug;35(4):294-306</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32384203</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Life Sci. 2000;67(10):1197-206</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10954053</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurochem. 2015 Jan;132(1):5-19</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25327899</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2014 Jun;20(6):659-63</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24793238</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Am Geriatr Soc. 2005 Apr;53(4):695-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15817019</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Clin Neuropsychol. 2017 Nov 1;32(7):810-828</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29077802</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Transfusion. 2012 May;52 Suppl 1:65S-79S</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22578374</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32253318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Psychol. 2014 Jul 22;5:772</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25101034</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurosci. 1999 May 1;19(9):3440-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">10212304</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Neurosci. 2006 Sep 13;26(37):9365-75</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16971520</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Qual Life Res. 2009 Jun;18(5):585-95</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19396572</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Dir Psychol Sci. 2012 Feb;21(1):8-14</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22773897</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2007 Oct 4;357(14):1450-1</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17914053</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Med Clin North Am. 2012 May;96(3):421-31, ix</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22703849</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2011 Aug 31;477(7362):90-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21886162</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Blood Transfus. 2016 Mar;14(2):152-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26674811</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2009 Jun 13;373(9680):2055-66</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19524782</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Pharm Des. 2005;11(8):999-1016</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15777250</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Neurosci Lett. 1994 May 19;172(1-2):151-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">8084523</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Mov Disord. 2012 Mar;27(3):349-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">22275317</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Autoimmun Rev. 2016 Oct;15(10):1005-11</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27497913</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>États-Unis</li>
</country>
<region><li>Californie</li>
<li>Floride</li>
<li>Michigan</li>
</region>
</list>
<tree><country name="États-Unis"><region name="Californie"><name sortKey="Parker, Jordan E" sort="Parker, Jordan E" uniqKey="Parker J" first="Jordan E" last="Parker">Jordan E. Parker</name>
</region>
<name sortKey="Anidi, Chioma M" sort="Anidi, Chioma M" uniqKey="Anidi C" first="Chioma M" last="Anidi">Chioma M. Anidi</name>
<name sortKey="Bronte Stewart, Helen M" sort="Bronte Stewart, Helen M" uniqKey="Bronte Stewart H" first="Helen M" last="Bronte-Stewart">Helen M. Bronte-Stewart</name>
<name sortKey="Bronte Stewart, Helen M" sort="Bronte Stewart, Helen M" uniqKey="Bronte Stewart H" first="Helen M" last="Bronte-Stewart">Helen M. Bronte-Stewart</name>
<name sortKey="Coburn, Maria" sort="Coburn, Maria" uniqKey="Coburn M" first="Maria" last="Coburn">Maria Coburn</name>
<name sortKey="Coburn, Maria" sort="Coburn, Maria" uniqKey="Coburn M" first="Maria" last="Coburn">Maria Coburn</name>
<name sortKey="Deutsch, Gayle K" sort="Deutsch, Gayle K" uniqKey="Deutsch G" first="Gayle K" last="Deutsch">Gayle K. Deutsch</name>
<name sortKey="Kapphahn, Kristopher I" sort="Kapphahn, Kristopher I" uniqKey="Kapphahn K" first="Kristopher I" last="Kapphahn">Kristopher I. Kapphahn</name>
<name sortKey="Lising, Melanie" sort="Lising, Melanie" uniqKey="Lising M" first="Melanie" last="Lising">Melanie Lising</name>
<name sortKey="Martinez, Amaris" sort="Martinez, Amaris" uniqKey="Martinez A" first="Amaris" last="Martinez">Amaris Martinez</name>
<name sortKey="Neuville, Raumin" sort="Neuville, Raumin" uniqKey="Neuville R" first="Raumin" last="Neuville">Raumin Neuville</name>
<name sortKey="Prabhakar, Varsha" sort="Prabhakar, Varsha" uniqKey="Prabhakar V" first="Varsha" last="Prabhakar">Varsha Prabhakar</name>
<name sortKey="Shah, Neil" sort="Shah, Neil" uniqKey="Shah N" first="Neil" last="Shah">Neil Shah</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidStanfordV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000289 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000289 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidStanfordV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:32633860
   |texte=   Safety of Plasma Infusions in Parkinson's Disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:32633860" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidStanfordV1

This area was generated with Dilib version V0.6.38.
Data generation: Tue Feb 2 21:24:25 2021. Site generation: Tue Feb 2 21:26:08 2021

	Serveur d'exploration sur le Covid à Stanford
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur le Covid à Stanford

Safety of Plasma Infusions in Parkinson's Disease.

Safety of Plasma Infusions in Parkinson's Disease.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki